Literature DB >> 11238223

Are the opsonophagocytic activities of antibodies in infant sera measured by different pneumococcal phagocytosis assays comparable?

M Väkeväinen1, W Jansen, E Saeland, I Jonsdottir, H Snippe, A Verheul, H Käyhty.   

Abstract

Host protection against Streptococcus pneumoniae is mainly mediated by opsonin-dependent phagocytosis. Several techniques for measuring opsonophagocytic activity (OPA) of antibodies to S. pneumoniae have been standardized and used. These include the viable cell-assay, flow-cytometric assays, and an assay utilizing radiolabeled bacteria. Using these different methods, we measured the OPA of antibodies to S. pneumoniae types 6B and 19F from the sera of infants immunized with a pneumococcal conjugate vaccine, PncCRM. Generally, the results obtained by the various techniques correlated well, although serotype-specific differences were found (6B, r = 0.78 to 0.95, P < 0.001; 19F, r = 0.50 to 0.84, P < 0.001). The same serotype-specific differences were observed for the relationship between the concentrations of specific immunoglobulin G antibodies measured by enzyme immunoassay and the OPA. Since the sensitivities of the OPA assays differed, the most prominent discrepancies between the techniques were found at low antibody concentrations.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11238223      PMCID: PMC96064          DOI: 10.1128/CDLI.8.2.363-369.2001

Source DB:  PubMed          Journal:  Clin Diagn Lab Immunol        ISSN: 1071-412X


  18 in total

1.  Contribution of serotype-specific IgG concentration, IgG subclasses and relative antibody avidity to opsonophagocytic activity against Streptococcus pneumoniae.

Authors:  M Anttila; M Voutilainen; V Jäntti; J Eskola; H Käyhty
Journal:  Clin Exp Immunol       Date:  1999-12       Impact factor: 4.330

2.  An analytical model applied to a multicenter pneumococcal enzyme-linked immunosorbent assay study.

Authors:  B D Plikaytis; D Goldblatt; C E Frasch; C Blondeau; M J Bybel; G S Giebink; I Jonsdottir; H Käyhty; H B Konradsen; D V Madore; M H Nahm; C A Schulman; P F Holder; T Lezhava; C M Elie; G M Carlone
Journal:  J Clin Microbiol       Date:  2000-06       Impact factor: 5.948

3.  A flow cytometric opsonophagocytic assay for measurement of functional antibodies elicited after vaccination with the 23-valent pneumococcal polysaccharide vaccine.

Authors:  J E Martinez; S Romero-Steiner; T Pilishvili; S Barnard; J Schinsky; D Goldblatt; G M Carlone
Journal:  Clin Diagn Lab Immunol       Date:  1999-07

4.  Assignment of weight-based antibody units to a human antipneumococcal standard reference serum, lot 89-S.

Authors:  S A Quataert; C S Kirch; L J Wiedl; D C Phipps; S Strohmeyer; C O Cimino; J Skuse; D V Madore
Journal:  Clin Diagn Lab Immunol       Date:  1995-09

Review 5.  Pathogenesis of pneumococcal infection.

Authors:  E I Tuomanen; R Austrian; H R Masure
Journal:  N Engl J Med       Date:  1995-05-11       Impact factor: 91.245

6.  Quantitative relationship between anticapsular antibody measured by enzyme-linked immunosorbent assay or radioimmunoassay and protection of mice against challenge with Streptococcus pneumoniae serotype 4.

Authors:  D M Musher; B Johnson; D A Watson
Journal:  Infect Immun       Date:  1990-12       Impact factor: 3.441

7.  Serum samples from infants vaccinated with a pneumococcal conjugate vaccine, PncT, protect mice against invasive infection caused by Streptococcus pneumoniae serotypes 6A and 6B.

Authors:  E Saeland; H Jakobsen; G Ingolfsdottir; S T Sigurdardottir; I Jonsdottir
Journal:  J Infect Dis       Date:  2000-12-08       Impact factor: 5.226

8.  Pneumococcal polysaccharide-meningococcal outer membrane protein complex conjugate vaccine is immunogenic in infants and children.

Authors:  H Käyhty; H Ahman; P R Rönnberg; R Tillikainen; J Eskola
Journal:  J Infect Dis       Date:  1995-11       Impact factor: 5.226

Review 9.  Pneumococcal virulence factors and host immune responses to them.

Authors:  D A Watson; D M Musher; J Verhoef
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1995-06       Impact factor: 3.267

10.  Opsonization and antibodies to capsular and cell wall polysaccharides of Streptococcus pneumoniae.

Authors:  G Vitharsson; I Jónsdóttir; S Jónsson; H Valdimarsson
Journal:  J Infect Dis       Date:  1994-09       Impact factor: 5.226

View more
  10 in total

1.  Specificities and opsonophagocytic activities of antibodies to pneumococcal capsular polysaccharides in sera of unimmunized young children.

Authors:  Anu Soininen; Maijastiina Karpala; Sirkka-Liisa Wahlman; Hannele Lehtonen; Helena Käyhty
Journal:  Clin Diagn Lab Immunol       Date:  2002-09

Review 2.  Use of HL-60 cell line to measure opsonic capacity of pneumococcal antibodies.

Authors:  R A Fleck; S Romero-Steiner; M H Nahm
Journal:  Clin Diagn Lab Immunol       Date:  2005-01

3.  Pneumococcal capsular polysaccharide vaccine-mediated protection against serotype 3 Streptococcus pneumoniae in immunodeficient mice.

Authors:  Haijun Tian; Avi Groner; Marianne Boes; Liise-anne Pirofski
Journal:  Infect Immun       Date:  2007-01-12       Impact factor: 3.441

Review 4.  Use of opsonophagocytosis for serological evaluation of pneumococcal vaccines.

Authors:  Sandra Romero-Steiner; Carl E Frasch; George Carlone; Roland A Fleck; David Goldblatt; Moon H Nahm
Journal:  Clin Vaccine Immunol       Date:  2006-02

5.  Post hoc analysis of a randomized double-blind trial of the correlation of functional and binding antibody responses elicited by 13-valent and 7-valent pneumococcal conjugate vaccines and association with nasopharyngeal colonization.

Authors:  Christine Juergens; Scott Patterson; James Trammel; David Greenberg; Noga Givon-Lavi; David Cooper; Alejandra Gurtman; William C Gruber; Daniel A Scott; Ron Dagan
Journal:  Clin Vaccine Immunol       Date:  2014-07-02

6.  Type-specific antibodies to pneumococcal capsular polysaccharide acquired either naturally or after vaccination with Prevenar in children with underlying chronic or recurrent lung diseases.

Authors:  David Navarro; Amparo Escribano; Laura Cebrián; Concepción Gimeno; Leonor García-Maset; Juan García-de-Lomas
Journal:  Clin Vaccine Immunol       Date:  2006-06

7.  Multilaboratory evaluation of a viability assay for measurement of opsonophagocytic antibodies specific to the capsular polysaccharides of Streptococcus pneumoniae.

Authors:  Sandra Romero-Steiner; Carl Frasch; Nelydia Concepcion; David Goldblatt; Helena Käyhty; Merja Väkeväinen; Craig Laferriere; Dominique Wauters; Moon H Nahm; Mark F Schinsky; Brian D Plikaytis; George M Carlone
Journal:  Clin Diagn Lab Immunol       Date:  2003-11

8.  Risk factors in HIV-1-infected patients developing repetitive bacterial infections: toxicological, clinical, specific antibody class responses, opsonophagocytosis and Fc(gamma) RIIa polymorphism characteristics.

Authors:  A Payeras; P Martinez; J Milà; M Riera; A Pareja; J Casal; N Matamoros
Journal:  Clin Exp Immunol       Date:  2002-11       Impact factor: 4.330

Review 9.  Correlates of Protection for M Protein-Based Vaccines against Group A Streptococcus.

Authors:  Shu Ki Tsoi; Pierre R Smeesters; Hannah R C Frost; Paul Licciardi; Andrew C Steer
Journal:  J Immunol Res       Date:  2015-05-25       Impact factor: 4.818

10.  Prime-boost vaccination strategy enhances immunogenicity compared to single pneumococcal conjugate vaccination in patients receiving conventional DMARDs, to some extent in abatacept but not in rituximab-treated patients.

Authors:  Per Nived; Göran Jönsson; Bo Settergren; Jon Einarsson; Tor Olofsson; Charlotte Sværke Jørgensen; Lillemor Skattum; Meliha C Kapetanovic
Journal:  Arthritis Res Ther       Date:  2020-02-22       Impact factor: 5.156

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.